A important advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This new offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://tiffanyujiu545104.eqnextwiki.com/5725801/groundbreaking_development_tirzepatide_dose_for_glucose_control